Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell 4D Molecular Therapeutics (4DMT) Stock

4D Molecular Therapeutics (4DMT) Stock

4dmoleculartherapeutics.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $109MM

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.

Learn more about 4D Molecular Therapeutics (4DMT) IPO

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to 4D Molecular Therapeutics (4DMT) before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like 4D Molecular Therapeutics (4DMT) before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

4D Molecular Therapeutics (4DMT) stock FAQs

plusminus

Can you buy 4D Molecular Therapeutics (4DMT) stock?

You can no longer buy 4D Molecular Therapeutics (4DMT) stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy 4D Molecular Therapeutics (4DMT) stock?

To invest in a private company like 4D Molecular Therapeutics (4DMT) through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell 4D Molecular Therapeutics (4DMT) stock?

You can no longer sell stock of 4D Molecular Therapeutics (4DMT) on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell 4D Molecular Therapeutics (4DMT) stock?

If you hold private company shares of 4D Molecular Therapeutics (4DMT) - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your 4D Molecular Therapeutics (4DMT) stock on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is 4D Molecular Therapeutics (4DMT) a public company?

No, 4D Molecular Therapeutics (4DMT) is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is 4D Molecular Therapeutics (4DMT)’s stock price?

The stock price of 4D Molecular Therapeutics (4DMT) is $17.05 as of 1/18/24.
plusminus

What is 4D Molecular Therapeutics (4DMT)’s stock ticker symbol?

The ticker symbol of 4D Molecular Therapeutics (4DMT) is FDMT.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Explore private companies in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
Element Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.05B

Team

Management Team

David Kirn MD
Chief Executive Officer, Chairman & Co-Founder
Melissa Kotterman Ph.D
Vice President, Discovery & Engineering & Co-Founder
August Moretti JD
Chief Financial Officer
Fred Kamal Ph.D
Chief Technology Officer
Peter Francis MD
Chief Medical Officer
Theresa Janke
Co-Founder & Chief Operating Officer
Leisa Johnson
Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area
David Schaffer Ph.D
Co-Founder, Chief Scientific Advisor & Board Member

Board Members

Charles Theuer MD
Self
Deborah Marshall JD
Sidley Austin
Margi McLaughlin Ph.D
Self
David Schaeffer Ph.D
Hoyoung Huh Ph.D
Self
David Kirn MD
4DMT
Jacob Chacko MD
Self
Tony Yao Ph.D
ArrowMark Partners
police 01/01/2024

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

Astellas Pharma has signed a $962m deal with 4D Molecular Therapeutics (4DMT) for rights to use one of 4DMT's gene therapy vectors for treating a rare eye disease. The US genetic medicines company will receive $20m upfront for its R100 vector technology and could receive up to $942.5m in future fees and milestones. Astellas will be responsible for research, development, manufacturing, and commercialisation and has an option to add two more disease targets.
globeNewswire 10/30/2023

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

4D Molecular Therapeutics (4DMT) has achieved alignment with the FDA over a plan to lift a clinical hold on the Phase 1/2 INGLAXA clinical trial involving 4D-310, a treatment for Fabry disease cardiomyopathy. The company has amended the INGLAXA protocol to decrease the risk of atypical hemolytic uremic syndrome (aHUS), and interim clinical data from the trial is expected to be presented in Q1 2024.
PharrmExec 07/12/2023

Astellas, 4D Molecular Therapeutics Agree to Licensing Deal

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have agreed to a licensing deal that allows Astellas to use 4DMT's intravitreal retinotropic R100 vector. The R100 vector is used for the delivery of genetic payloads in the treatment of retinal diseases. Astellas initially has rights to one genetic target, with the option to include two more for additional fees.
Fierce Biotech 07/10/2023

Astellas paves backloaded biobucks deal to test 4DMT's eye disease gene therapy vector

Astellas Pharma has signed a contract to use 4D Molecular Therapeutics’ gene therapy vector for at least one rare eye disease. As part of the deal, 4DMT will receive $20 million upfront, with potential total milestones of $942.5 million. Astellas will use the vector to deliver its own genetic payloads and will be responsible for R&D, manufacturing, and commercialization for the resulting programs. The deal aligns with Astellas' focus on blindness and regeneration as part of its R&D strategy.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.